Despite “false allegations”, Massucci and his defense attorneys believed the case was pushed forward by Prescott police ...
Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback